Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261


Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients with refractory solid cancers.   Phase 1 dose escalation continues, and future plans include initiation of an expansion